Karyopharm Therapeutics Inc. — Form 8-K
Filed September 18, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 72/100
What the filing says
Karyopharm Therapeutics designated and created 20,000 authorized shares of 0% Series A Convertible Perpetual Preferred Stock on September 17, 2026. The preferred stock has a $1,000 initial liquidation preference per share, converts to common stock at $1.62/share (226 shares initially), ranks senior to common stock on liquidation, and grants holders repurchase rights upon fundamental change or on/after September 17, 2029 (put trigger date). The filing is a certificate of designations establishing the terms; it does not specify the number of shares actually issued or the identity of investors.
Why this rating
Significant financing/capital event for $37M company. Preferred stock structure with conversion, liquidation preference, and put rights is material to capital stack. However, shares authorized but not yet issued; actual issuance amounts and investor identity unknown. Terms include restrictions and anti-dilution provisions common in distressed financings.
Price action (we called it neutral)
before filing · preread $1.88 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 18, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.